Infectious Bronchitis Virus (ibv) Patents (Class 424/222.1)
  • Patent number: 9492548
    Abstract: The present invention pertains to an emulsion comprising an aqueous phase and an oily phase, the aqueous phase containing a non-live medicinal substance, wherein the aqueous phase comprises at least 30% w/w sugar. The invention also pertains to a method to shield a medicinal substance present in an aqueous phase emulsified with an oily phase, from interaction with the oily phase, and to a vaccine comprising as an antigen a killed micro-organism or a subunit of a micro-organism, the antigen being present in an aqueous phase that is dispersed in an oily phase, wherein the aqueous phase comprises at least 30% w/w sugar.
    Type: Grant
    Filed: December 11, 2013
    Date of Patent: November 15, 2016
    Assignee: Intervet Inc.
    Inventors: Erwin Mombarg, Theodorus Jansen, Henricus Johannes Maria Jagt
  • Publication number: 20150086590
    Abstract: A vaccine composition for birds comprising as an active ingredient a structure containing O-antigen derived from Gram-negative bacteria, provided that said structure does not contain a whole cell, and a process for preparing the same are provided. By using a structure containing O-antigen (e.g. lipopolysaccharide) derived from Gram-negative bacteria as an active ingredient in accordance with the present invention, alleviation of inoculation reaction and reduction in an amount of injection are attained as compared to the conventional whole-cells vaccine to thereby allow for the increase in the number of other antigens to be mixed therewith.
    Type: Application
    Filed: February 19, 2013
    Publication date: March 26, 2015
    Applicant: THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE
    Inventors: Ryuichi Sakamoto, Masashi Sakaguchi
  • Patent number: 8828407
    Abstract: The present invention provides a chimaeric coronavirus S protein which is based on an S protein from a coronavirus strain with restricted tissue tropism, but which comprises at least part of the S2 subunit from a coronavirus strain with extended tissue tropism, such that a virus comprising the chimaeric S protein has extended tissue tropism. The present invention also provides a virus comprising such a chimaeric S protein.
    Type: Grant
    Filed: July 5, 2010
    Date of Patent: September 9, 2014
    Assignee: The Pirbright Institute
    Inventors: Paul Britton, Erica Bickerton, Maria Armesto
  • Publication number: 20140199345
    Abstract: The present invention relates to immunostimulatory oligodeoxynucleotides, vectors and vaccines comprising such oligodeoxynucleotides, to their use as a medicament, to their use in preventing or combating infectious disease, to methods for the detection of such oligodeoxynucleotides and to cells to be used in these methods.
    Type: Application
    Filed: May 25, 2012
    Publication date: July 17, 2014
    Inventors: Carla Christina Schrier, Simon Ilg
  • Publication number: 20140193457
    Abstract: The present invention relates to immunostimulatory oligodeoxynucleotides, vectors and vaccines comprising such oligodeoxynucleotides, to their use as a medicament, to their use in preventing or combating infectious disease and to methods for the detection of such oligodeoxynucleotides.
    Type: Application
    Filed: May 25, 2012
    Publication date: July 10, 2014
    Inventors: Carla Christina Schrier, Simon ILG
  • Publication number: 20140127264
    Abstract: The present invention relates to Infectious bronchitis virus (IBV) spike protein or a fragment thereof comprising a receptor-binding domain, wherein said spike protein or said fragment thereof is C-terminally fused to a trimerisation or tetramerisation domain. Such proteins form trimer or tetramer structures and as such they mimic the natural context of the spike protein. The present invention further relates to subunit vaccines comprising such a protein, to DNA molecules encoding such proteins, to plasmids comprising such DNA molecules, to avian live recombinant carrier viruses (LRCV's) comprising such DNA molecules or plasmids, to vaccines comprising such DNA molecules, plasmids and LRCV's and to combination vaccines comprising an IBV spike protein, DNA molecules, plasmids or LRCV's encoding such a protein, and another IBV vaccine capable of inducing protection against another IBV serotype and/or a vaccine capable of inducing protection against another avian pathogen.
    Type: Application
    Filed: March 1, 2012
    Publication date: May 8, 2014
    Inventors: Hèélne Verheije, Carla Christina Schrier
  • Publication number: 20120321663
    Abstract: A method for preparing a vaccine composition to be implemented in a locally administered treatment for avian viral disease, includes at least the step of: a) extemporaneously mixing a vaccine, including at least one live virus selected from a virus belonging to one or more strains of the avian disease, with an adjuvant diluent (DA), characterized in that the adjuvant diluent is a continuous aqueous phase oil-in-water emulsion or oil-in-water microemulsion.
    Type: Application
    Filed: March 15, 2011
    Publication date: December 20, 2012
    Applicant: SOCIETE D'EXPLOITATION DE PRODUITS POUR LES INDUSTRIES CHIMIQUES SEPPIC
    Inventors: Francois Bertrand, Sebastien Deville, Laurent Dupuis
  • Publication number: 20120121644
    Abstract: The present invention is directed to a composition, kit and method for delivering a soft flowable gel to a flock of poultry in barns, but can also be used in hatcheries or free range farms, for treating poultry with a therapeutic agent. The soft flowable gel comprises water, a gelling agent, a therapeutic agent and between about 0.05% and 0.15% xanthan gum.
    Type: Application
    Filed: July 27, 2010
    Publication date: May 17, 2012
    Inventor: Eng-Hong Lee
  • Publication number: 20110305726
    Abstract: The present invention relates to infectious bronchitis (IB) viruses derived from a recently identified genotype of IB virus known as IB-QX, or from viruses that are genetically related to IB-QX, herein referred to as IB-QX-like viruses. The IB viruses of the invention may be live and attenuated or inactivated. Live, attenuated IB viruses of the invention may be produced by serial passaging of an IB-QX-like virus. The IB viruses of the invention are useful for, inter alia, vaccines against IB-QX and IB-QX-like viruses. Heretofore, known vaccine strains of IB viruses have proven insufficient to protect against infectious bronchitis caused by IB-QX and IB-QX-like viruses.
    Type: Application
    Filed: August 7, 2009
    Publication date: December 15, 2011
    Applicant: Wyeth LLC
    Inventors: Harmen Jacob Geerligs, Cindy Aleida Maria Meinders, Geert Jan Boelm, Bastiana Geertruida Elisabeth Stuurman
  • Publication number: 20110268762
    Abstract: The present invention relates generally to the fields of immunology and vaccine technology. More specifically, the invention relates to mucosal administration via aerosol spray to avians of immunogenic and vaccine compositions, including those comprising recombinant human adenovirus vectors for delivery of genes encoding avian immunogens or antigens, such as genes encoding avian influenza virus. The invention also provides methods and apparatus for use in such administration.
    Type: Application
    Filed: March 25, 2011
    Publication date: November 3, 2011
    Inventors: Haroldo Toro, De-Chu C. Tang, Kent R. Van Kampen
  • Publication number: 20110223195
    Abstract: The invention relates to vaccine compositions comprising chitosan and a vaccine which are administered to avian species via the ocular route, and methods or programs of vaccination including use of chitosan in order to increase or enhance cell-mediated immunity in avian species and persistence of the vaccine avian tissues.
    Type: Application
    Filed: September 4, 2009
    Publication date: September 15, 2011
    Applicant: CEVA SANTE ANIMALE SA
    Inventors: Yannick Gardin, Vilmos Palya, Sylvain Comte
  • Patent number: 7951781
    Abstract: Embodiments include compositions and methods for lower the surface tension of a liquid-air interface by contacting such interface with all or part of a PLUNC polypeptide.
    Type: Grant
    Filed: November 2, 2007
    Date of Patent: May 31, 2011
    Assignee: University of Iowa Research Foundation
    Inventors: Paul B. McCray, Jr., Lokesh Gakhar, Rama K. Mallampalli, Subramanian Ramaswamy, Jennifer Bartlett
  • Publication number: 20100150958
    Abstract: The invention relates to new vaccine compositions for vaccinating birds.
    Type: Application
    Filed: November 18, 2009
    Publication date: June 17, 2010
    Applicant: VECTOGEN PTY LTD.
    Inventor: Michael Sheppard
  • Publication number: 20100062019
    Abstract: The present invention provides for a novel oil-in-water (O/W) emulsion, with increased stability in the presence of bacterial or viral suspensions, especially those concentrated and non-purified or weakly purified. The emulsion of the present invention can act as vehicle for the delivery of a pharmaceutical composition comprising at least one immunogen and, in particular, an immunogen selected from the group comprising an inactivated pathogen, an attenuated pathogen, a subunit, a recombinant expression vector, and a plasmid or combinations thereof.
    Type: Application
    Filed: September 10, 2009
    Publication date: March 11, 2010
    Inventors: Alexis Guy Andre Parisot, Stephanie Marie-Catherine Desgouilles-Blechet, Catherine Charreyre
  • Publication number: 20100003279
    Abstract: A purpose of the present invention is to provide a vaccine for in ovo inoculation effective for prevention of any fowl viral diseases. A fowl vaccine for in ovo inoculation with high efficacy in view of safety as well wherein, by holding such live viruses on a virus-adsorbing agent through adsorption that have been difficult for practical usage as a vaccine for in ovo inoculation, viral growth in embryonated chicken eggs after in ovo inoculation is retarded to thereby reduce pathogenicity of the viruses to embryo to avoid reduction in hatching rate and to alleviate severity in clinical symptoms after hatching. A virus-adsorbing agent to be used in the vaccine includes an aluminum compound such as aluminum hydroxide gel, potassium alum and the like.
    Type: Application
    Filed: December 21, 2006
    Publication date: January 7, 2010
    Applicant: JURIDICAL FOUNDATION THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE
    Inventors: Ohta Hideyuki, Shinsuke Ezoe, Kenichi Yamazaki, Toru Kawai
  • Publication number: 20090041852
    Abstract: This invention provides a dry powder composition for poultry vaccination via inhalation comprising an effective amount of a poultry vaccine agent, and a supporting amount of carriers for said poultry vaccine agent, said carriers comprising a combination of a reducing or non-reducing sugar and a biocompatible polymer, said dry powder composition being in the form of particles having an average particle size from 2 to 30 ?m and a particle size polydispersity from 1.1 to 4.0. This invention also relates to a method for producing said dry powder compositions and a system for vaccination of poultry by inhalation.
    Type: Application
    Filed: March 15, 2007
    Publication date: February 12, 2009
    Applicant: UNIVERSITEIT GENT
    Inventors: Jean Paul Remon, Chris Vervaet, Evy Corbanie
  • Patent number: 7445785
    Abstract: The present invention provides a vaccine for use in the protection of poultry against infectious bronchitis comprising an attenuated infectious bronchitis virus (IBV) and a pharmaceutical acceptable carrier or diluent, characterized in that the attenuated IBV comprises a heterologous spike gene. Such a vaccine is based on IBV strain Beaudette that is able to express a spike gone derived from a different IBV strain. The vaccines provided by the present invention also allow the administration via the in ovo route.
    Type: Grant
    Filed: March 3, 2004
    Date of Patent: November 4, 2008
    Assignees: Intervet International B.V., Institute for Animal Health
    Inventors: David Cavanagh, Paul Britton, Ian Tarpey
  • Patent number: 7291342
    Abstract: Embodiments of the present invention generally relate to a novel attenuated infectious bronchitis virus (IBV) of GA-98 isolate. Further, other embodiments of the present invention generally relate to methods of immunizing avian against an infectious bronchitis virus. As well, further embodiments relate to method of making a vaccine and/or immunogenic composition for protecting avian, such as poultry, from an infectious bronchitis virus of strain GA-98.
    Type: Grant
    Filed: May 17, 2004
    Date of Patent: November 6, 2007
    Assignee: Intervet International B.V.
    Inventors: Lillian Melson, Faris Jirjis
  • Patent number: 7192588
    Abstract: The present invention relates to a stable compacted, compressed or hard tableted injectable composition, including a vaccine composition comprising at least one freeze dried antigenic component and a dissolution aid. A package containing the above injectable composition and method to facilitate immunizing a subject against a disease comprising the steps of first dissolving the compacted, compressed or hard tableted vaccine composition in a package with a diluent to form a vaccine solution, and administering the resulting vaccine solution in an amount effective for immunizing is also provided.
    Type: Grant
    Filed: June 10, 2002
    Date of Patent: March 20, 2007
    Assignee: Teva Pharmaceutical Industries, Ltd.
    Inventors: Gilad Gallili, Norbert Frydman
  • Patent number: 7037506
    Abstract: The present invention provides a vaccine accelerator factor (VAF) which is an in ovo nucleotide immuno-stimulant. The VAF contains one or more DNA constructs, each having a DNA molecule and a vector. Each of the DNA molecule contains one or more genes or gene fragments, each encoding an antigenic peptide of an avian virus. The VAF is preferably administered to the amniotic fluid of an egg after being fertilized for about 17–19 days. The VAF can be co-administered with a viral vaccine containing one or more attenuated or inactive avian viruses. Alternatively, the VAF can be administered prior to the administration of the viral vaccine, which is administered at hatch or post-hatch. The VAF stimulates and accelerate a protective immune response of a viral vaccine.
    Type: Grant
    Filed: May 6, 2003
    Date of Patent: May 2, 2006
    Assignee: Schweltzer Chemical Corporation Ltd.
    Inventor: Tsun Yung Kuo
  • Publication number: 20040265339
    Abstract: Embodiments of the present invention generally relate to a novel attenuated infectious bronchitis virus (IBV) of GA-98 isolate. Further, other embodiments of the present invention generally relate to methods of immunizing avian against an infectious bronchitis virus. As well, further embodiments relate to method of making a vaccine and/or immunogenic composition for protecting avian, such as poultry, from an infectious bronchitis virus of strain GA-98.
    Type: Application
    Filed: May 17, 2004
    Publication date: December 30, 2004
    Inventors: Lillian Melson, Faris F. Jirjis
  • Publication number: 20020081316
    Abstract: The present invention provides a novel avian herpesvirus (NAHV) vector and recombinant vaccines made therefrom that are useful to immunize avian species against Marek's disease, infectious laryngotracheitis and Newcastle disease. Methods of immunizing an avian species against Marek's disease, infectious laryngotracheitis and Newcastle disease are also provided.
    Type: Application
    Filed: June 14, 2001
    Publication date: June 27, 2002
    Inventors: Mark D. Cochran, Stephanie M. Cook, Martha A. Wild
  • Patent number: 6340464
    Abstract: Vaccine adjuvants comprising a liquid medium contain polymers with anionic constitutive repeating units and hydrophobic constitutive repeating units. Advantageously, the adjuvants are aqueous solutions of partially esterified polyacrylic acids. The novel adjuvants are highly stable, effective and have a relatively low level of local toxicity. Further, vaccines comprising such adjuvants and a process for producing them are described.
    Type: Grant
    Filed: September 3, 1997
    Date of Patent: January 22, 2002
    Assignee: American Cyanamid Company
    Inventors: Luuk Hilgers, Michel Strebelle
  • Patent number: 6299874
    Abstract: A method of producing active immunity against a viral disease in an animal subject comprises administering to the subject a vaccine conjugate consisting essentially of a live virus and a neutralizing factor bound to the live virus. The neutralizing factor is selected from the group consisting of antibodies and antibody fragments. The live virus is one capable of producing disease in the subject, and the antibody or antibody fragment is one capable of neutralizing the live virus. Preferred subjects are birds, a preferred virus is Infectious Bursal Disease Virus, and a preferred route of administration to birds is by in ovo administration.
    Type: Grant
    Filed: July 11, 2000
    Date of Patent: October 9, 2001
    Assignee: University of Arkansas
    Inventors: Craig E. Whitfill, John A. Thoma, Tommy L. Fredericksen, Julius K. Tyczkowski, J. Paul Thaxton, Jr.
  • Patent number: 6183753
    Abstract: This invention provides a recombinant herpesvirus of turkeys-Marek's disease virus chimera comprising a herpesvirus of turkeys unique long viral genome region and a Marek's disease virus unique short viral genome region.
    Type: Grant
    Filed: February 21, 1997
    Date of Patent: February 6, 2001
    Assignee: Schering-Plough Veterinary Corp.
    Inventors: Mark D. Cochran, Martha A. Wild, Barbara J. Winslow